While 2025 was the year of disruption for Trump’s pharma policies, we expect 2026 to be the year of truth: will the US ...

Each article in this bundle – or each track on pharma’s White Album, if you will – opens with our key calls for 2026 (Side A) ...

China has rapidly become a leading hub for innovative new medicines, overtaking Europe and putting the continent at risk of ...

We expect strong CDMO growth in 2026, driven by geopolitical fragmentation and regional manufacturing consolidation ...

M&A is an important part of pharmaceutical innovation, as 40% to 50% of industry innovation comes from acquired assets ...

The latest UK jobs report suggests those concerns are overblown Here's what the latest UK jobs report tells us: Unemployment ...

For common painkillers, Europe is entirely reliant on Asia; its last paracetamol factory closed in 2008, for instance. In ...

The tensions between the US and EU are only having a mild impact on markets thus far, but we do expected a bullish mood in ...

A further sell-off in JGBs would seem to drag USD/JPY towards intervention territory at 159/160. However, if the yen sell-off ...

A weaker US dollar provided some support to oil and the broader commodities complex. Continued firmness in ICE Brent timespreads will also help buoy the market, as it suggests a tighter spot physical ...

At this point, the outcome of these new trade tensions is unclear, but what has long been evident is that there is no such ...

Regulators should incentivise the adoption of cutting-edge technology rather than focus on driving prices down ...